Related references
Note: Only part of the references are listed.Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2012)
The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets
Ju Dong Yang et al.
SEMINARS IN CANCER BIOLOGY (2011)
The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases
Rajeev S. Bhide et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells
Aleksandar Sokolovic et al.
FIBROGENESIS & TISSUE REPAIR (2010)
PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling
Yuqing Liu et al.
LABORATORY INVESTIGATION (2009)
Therapeutic targeting of the PDGF and TGF-β-signaling pathways in hepatic stellate cells by PTK787/ZK22258
Yuqing Liu et al.
LABORATORY INVESTIGATION (2009)
Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
Hung Huynh et al.
CLINICAL CANCER RESEARCH (2008)
TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse
Afsan Kahraman et al.
HEPATOLOGY (2008)
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)
Zhen-Wei Cai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist
Mark Ayers et al.
CANCER RESEARCH (2007)
STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity
Won-Il Jeong et al.
HEPATOLOGY (2006)
Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice
Piotr Czochra et al.
JOURNAL OF HEPATOLOGY (2006)
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor
RS Bhide et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Therapeutic strategies against TGF-β signaling pathway in hepatic fibrosis
XJ Liu et al.
LIVER INTERNATIONAL (2006)
Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma
JS Campbell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis
L Xu et al.
GUT (2005)
Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis
CD Yu et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
A mouse model of hepatocellular carcinoma - Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice
K Nicholes et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Share Paper
